Patient reporting encouragedduring monitoringof dapoxetine in New Zealand

Drug Safety

Volumn 34, Issue 11, 2011, Pages 1115-1116

  Harrison Woolrych, Mira ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Adverse reaction monitoring; Dapoxetine; Patient education

Indexed keywords

DAPOXETINE; BENZYLAMINE DERIVATIVE; NAPHTHALENE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

DRUG SURVEILLANCE PROGRAM; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LETTER; NEW ZEALAND; PREMATURE EJACULATION; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; DRUG EFFECT; DRUG MONITORING; EJACULATION; MALE; METHODOLOGY; PATIENT SATISFACTION; QUESTIONNAIRE; SEXUAL DYSFUNCTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; BENZYLAMINES; DRUG MONITORING; EJACULATION; HUMANS; MALE; NAPHTHALENES; NEW ZEALAND; PATIENT SATISFACTION; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL;

EID: 80053922295     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11596010-000000000-00000     Document Type: Letter

References (3)

1. Harrison-Woolrych M, Coulter DM. PEM in New Zealand. In: Mann R, Andrews EB, editor. Pharmacovigilance. 2nd ed. Chichester: John Wiley and Sons Ltd, 2007: 313-28
2. Janssen-Cilag L. Priligy data sheet. 2011 [online]. Available from URL: http://www.medsafe.govt.nz/profs/Datasheet/p/Priligytab.pdf [Accessed 2011 Jun]
3. Van Grootheest K, van Puijenbroek E. Pharmacovigilance in the Netherlands. In: Mann R, Andrews EB, editor. Pharmaco-vigilance. 2nd ed. Chichester: John Wiley and Sons Ltd, 2007: 277-85.